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Background/aim: The purpose of the present study was to investigate whether endothelial nitric oxide synthase (eNOS) gene
polymorphisms play a role in prostate cancer (PCa).
Materials and methods: We examined three eNOS gene polymorphisms (T-786C promoter region, G894T, and Intron 4 VNTR 4a/b)
at extracted DNAs from 50 formalin-fixed paraffin-embedded tissues of PCa patients. For the controls, blood samples obtained from 50
healthy men were studied. Genotyping of molecular variants was performed by PCR-RFLP technique.
Results: We found that the TC genotype of the T-786C polymorphism was associated with PCa risk (OR: 3.325, CI: 1.350–8.188, P =
0.008). The eNOS G894T polymorphism was also associated with PCa. The frequency of the 894T allele was significantly higher in PCa
patients. No association was identified between intron 4 VNTR polymorphism and PCa.
Conclusion: We found significant differences in genotypic and allelic frequencies between PCa patients and controls for eNOS T-786C
and G894T polymorphisms. The presence of the T-786C genotype and 894T allele in carriers increased the risk of PCa. No association
was found between intron 4 VNTR polymorphism and PCa patients.
Key words: Polymorphism, prostate cancer, eNOS

1. Introduction
Prostate cancer (PCa) incidence and mortality have
increased dramatically after 1970 (1). PCa, which is the
most common organ cancer in men, is the second leading
cause of death by tumor. It progresses silently, invades
locally or metastasizes in most patients with cancer. Most
frequently patients are diagnosed between ages 65 and 75
(2).
Nitric oxide synthase (NOS), which is an enzyme
family, catalyzes the conversion of L-Arginine to
L-Citrulline and produces reactive nitric oxide (NO)
molecules. There are 3 isoenzymes of NOS: neuronal nitric
oxide synthase (nNOS), inducible nitric oxide synthase
(iNOS), and eNOS. These enzymes are named according
to their location (3,4).
With genome-wide studies, some chromosome
regions, which are thought to have a role in PCa, have
been identified. Examples for these regions may be given
as 3p, 7q, 9q, 10q, 11p, 13q, 16q, 17p, and 18q (5,6). The
* Correspondence: fikriyepolat@gmail.com

eNOS gene is located on 7q35-36 and consists of 26 exons.
eNOS is a constitutively expressed enzyme of 135kDa in
vascular endothelial cells. Three polymorphisms of the
eNOS gene have been widely studied. The polymorphism
at codon 298 (rs1799983) in exon 7 of the eNOS gene, also
called G894T, is a functional polymorphism that results
in a Glu-Asp substitution during protein synthesis. eNOS
enzyme activity is found to be reduced in carriers with
this substitution when compared with GG homozygous
individuals. The second functional polymorphism of the
eNOS is the T/C point mutation (rs2070744) located at
nucleotide 786 close to 5’ terminus. Mutation at this site
causes a significant decrease in promoter activity. The third
functional polymorphism of the eNOS is 27-bp VNTR
(eNOS4a/b) in intron 4 and causes basal NO production
(4,7).
Studies on the relationship between eNOS gene
polymorphism and PCa are very scarce. Sanli et al. (8)
reported that the eNOS 4a/b allele was not associated with
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PCa. Safarinejad et al. (4) investigated the relationship
between eNOS gene polymorphisms (T-786C, G894T,
and intron 4 VNTR a/b) and clinical parameters of PCa;
they found association of PCa with T-786C or 4a/b eNOS
polymorphisms, but not with G894T. In their experimental
procedure, they extracted genomic DNA from peripheral
blood leukocytes. With regard to polymorphisms T-786C,
G894T, and intron 4 VNTR a/b, the present study is
the first to identify eNOS gene polymorphisms in the
formalin-fixed paraffin-embedded tissues of PCa patients.
The purpose of this study was to investigate whether eNOS
gene polymorphisms play any role in PCa (T-786C, G894T,
intron 4 VNTR a/b).
2. Materials and methods
2.1. Patients and controls
This study was performed with 50 formalin-fixed paraffinembedded tissues of PCa patients (35–72 years of age).
The samples with adenocarcinoma were chosen with
a combination of convenience and random sampling
methods. Firstly, the Department of Pathology in the
Faculty of Medicine at Cumhuriyet University was chosen
as a convenient sample group for its access. Then, 50
samples were randomly selected from the tissue samples
that were collected between 2009 and 2013 within the
Department of Pathology in the Faculty of Medicine at
the Cumhuriyet University Turkey. As the tissue samples
had been irreversibly anonymized, no clinical or patientrelated information was available for this study. From each
block 10-μm sections were cut on a standard microtome,
placed in individual Eppendorf tubes, and stored at 4 °C
until extraction.
A total of 50 individuals were evaluated as a control
group in this study. The control group was hospital-based
and selected from among healthy voluntary men whose
ages matched those of the patient group. Genomic DNA
was extracted from the whole blood treated with EDTA
using the QIAamp DNA Blood Mini Kit, according to the
manufacturer’s guidelines. The extracted DNA was stored
at –20 °C until analysis.
All procedures were performed in accordance with the
guidelines of the Human Ethics Committee of the Kocaeli
University School of Medicine (Ethic number: KOU
KAEK 2013/23).
2.2. Extraction of DNA from paraffin-embedded material
Using the method described by Mattes and Miller, DNA
was extracted from paraffin-embedded tissues of PCa
patients: 1) Tissue was deparaffinized in 1 mL of xylene
and incubated for 30 min at room temperature on rotary
shaker. 2) The material was then centrifuged at top speed
for 5 min and supernatant was discarded (this step was
repeated twice). 3) Ethanol (100%) (0.5 mL) was added
and mixed by inverting the tube 10 times. This mixture
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was centrifuged at top speed for 5 min, and supernatant
was discarded (this step was also repeated twice), and then
air-dried until the ethanol evaporated. 4) Digestion buffer
(50 mM Tris-HCl, pH: 8, 0.1 mM EDTA, and 0.5%Tween
20) (100 μL) containing proteinase K (20mg/mL) was
added and incubated for 3 h at 55 °C. 5) Samples were flash
spun to remove the liquid from the cap, heated at 95 °C for
8 min to inactivate the proteinase K, and incubated for 1 h
in ice. 6) The final DNA suspension was stored at –20 °C
until used for PCR; 2–5 μL in a 100 μL reaction volume
was used for PCR (9).
2.3. Molecular variants genotyping
The genotyping of eNOS gene polymorphisms was
determined with PCR as described by Safarinejad et al (4).
2.3.1. eNOS T-786C polymorphism
The eNOS T-786C genotypes were amplified by PCR with
the primers 5’- AAGGCAGGAGACAGTGGATGGA-3’
(forward) and 5’CCCAGTCAATCCCTTTGGTGCTCA-3’
(reverse) (4). The predicted PCR product size was 180
bp. The PCR products were digested with MspI (Thermo
scientific) at 37 °C overnight, separated by electrophoresis
on 2% agarose gels, and visualized under ultraviolet (UV)
illumination after ethidium bromide staining. The wildtype allele (allele “T”) contained two fragments, 140 and
40 bp. The Polymorphic variant (allele “C”) contained
three fragments, 90, 50, and 40 bp (Figure 1).
2.3.2. eNOS G894T polymorphism
The G894T polymorphisms was determined by PCR
followed by the restriction digestion using the following
primers
5’-TGGAGAGTGCTGGTGTACCCCA-3’
(forward) and 5’-GCCTCCACCCCCACCCTGTC-3’
(reverse) (4). PCR products were restricted by BanII
(Thermo scientific) at 37 °C overnight. The fragment sizes
were 163 and 85 bp for the wild-type or no digestion for
the variant allele. DNA fragments were separated on 2%
agarose gel electrophoresis (Figure 2).
2.3.3. 27 bp-VNTR polymorphism in intron 4
Genotypes of the 27-VNTR in intron 4 were
determined by PCR amplification using primers
5’-AGGCCCTATGGTAGTGCCTTT-3’ (forward) and
5’-TCTCTTAGTGCTGTGGTCAC-3’ (reverse) (4,10).
The genotypes were determined by fragments visualized
in 3% high-resolution agarose gel at 100 V for 75 min and
visualized under UV after ethidium bromide staining. The
wild type allele (allele “b”) contained five tandem repeats
of 27 bp and 420 bp; the mutant allele (allele “a”) contained
four tandem repeats of 27 bp and 393 bp band (Figure 3).
2.4. Statistical analysis
Statistical analysis was performed using SPSS version 18.
The frequencies of homozygous and heterozygous eNOS
gene mutations and the frequency of allelic mutations in
PCa patients and controls were compared using chi-square
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Figure 1. Detection of T-786C polymorphism. Lane 1: PCR product; lane 2: 50 bp DNA Marker; lane 3
and 6: control carrying wild-type alleles; lane 4: homozygote patient carrying a polymorphic allele; lane 5:
heterozygote patient carrying both the polymorphic and wild-type alleles.
Figure 2. Representative agarose gel PCR products of G894T homozygote (TT, lanes 1 and 2, 4 and 5, 7 and 8),
heterozygote (GT, lane 6), and wild-type (GG, lanes 9 and 10). A 50-bp marker was electrophoresed in lane 3.
Figure 3. Tandem 27 bp repeats in intron 4 VNTR polymorphism. Lanes 1–3: heterozygote genotype (intron
4 ab); lane 4: a standard 100-bp marker; lane 5: patient with 4 repeats of 27 bp (intron 4 aa genotype); lanes
6–8: patients with 5 repeats of 27 bp (intron 4 bb genotype).

analysis. For each polymorphism, unconditional logistic
regression was used to calculate odds ratios (ORs) and
95% confidence intervals (95% CI) for PCa. A value of P <
0.05 was considered significant. The significant mutation
profiles are discussed in the current report. Deviations
from the Hardy–Weinberg equilibrium were analyzed by
using the c2 test.
3. Results
In this study we analyzed 50 PCa patients and 50 healthy
controls. The table shows the allele and the genotype
frequencies of eNOS T-786C, G894T, and intron 4 VNTR
(4a/b) polymorphisms in PCa patients and controls. When
the genotype frequencies of these three polymorphisms
were evaluated, no deviation from the Hardy–Weinberg
equilibrium was observed for both cases and controls.
For the T-786C polymorphism of the eNOS gene, in
the PCa group 32 patients (64%) were TT genotype, 11
patients (22%) were TC genotype, and 7 patients (14%)
were CC genotype; in the control group, 21 healthy
individuals (42%) were TT genotype, 24 individuals
(48%) were TC genotype, and 5 individuals (10%) were

CC genotype. The TC genotype of the case group was also
significant compared with that of the control group (Table,
Figure 1), (OR: 3.325, CI: 1.350–8.188, P < 0.05).
A significant difference in both genotype distribution
and allele frequency between PCa patients and healthy
controls was found for the eNOS G894T polymorphism.
The GT and TT genotypes in PCa patients were higher
than those in the controls (44% and 54% respectively,
P < 0.05). The T allele frequency was 0.760 for PCa and
0.250 for healthy individuals in the current study. The
difference between the eNOS G894T polymorphism T
allele frequency in PCa patients and that in controls was
also significant (Table, Figure 2), (OR: 0.105, CI: 0.055–
0.201, P < 0.05).
No significant differences were observed between
the groups for the intron 4 VNTR genotype and allele
frequencies. The prevalence of genotypes of bb, ab, and aa
profiles for the eNOS intron VNTR polymorphism were
82%, 14%, and 4% respectively in patients with PCa, and
72%, 24%, and 4% respectively in the control group. The
“a” allele frequency was 0.110 in patients with PCa and
0.160 in the control group (Table, Figure 3).
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Table. Distribution of the genotype and allele frequencies of eNOS T-786C, G894T, and intron 4 VNTR polymorphisms
in patients with PCa and control subjects.
Patients
n=50 n/%

Control
n=50n/%

P value

Odds ratio

95% (CI)

TT

32 (64)

21 (42)

-

1

-

TC

11 (22)*

24 (48)

0.008

3.325

1.350-8.188

CC

7 (14)

5 (10)

0.896

1.088

0.305-3.887

T

75 (75)

66 (66)

C

25 (25)

34 (34)

0.117

1.628

0.884-2.999

GG

1 (2)

29 (58)

-

1

-

GT

22 (44)

17 (34)

0.0001

0.027

0.003-0.216

TT

27 (54)

4 (8)

0.0001

0.005

0.001-0.041

G

24 (24)

75 (75)

T

76 (76)**

25 (25)

0.0001

0.105

0.055-0.201

bb

41 (82)

36 (72)

-

1

-

ab

7 (14)

12 (24)

0.200

1.952

0.694-5.491

aa

2 (4)

2 (4)

0.899

1.139

0.153-8.504

b

89 (89)

84 (84)

a

11 (11)

16 (16)

0.301

1.541

0.676-3.512

Gene/genotypes
eNOS T-786C

Allelles
eNOS G894T

Allelles

eNOS Intron 4 VNTR

Allelles

*The TC genotype in eNOS T-786C SNP was significant for the patient group in the current PCa cohort; Odds ratio:
3.325 (1.350–8.188), P < 0.05; **The T allele in eNOS G894T SNP was significant for the patient group in the current
PCa cohort; Odds ratio: 0.105 (0.055–0.201), P < 0.05.

4. Discussion
NO has a specific biological role in the human body. It is
effective in physiological and pathological conditions, and
therefore its construction is controlled in a very precise way. Its
main physiological functions include vasodilation, inhibition
of platelet aggregation, neurotransmission, and regulation of
the immune response (11). Studies have highlighted the role
of NO in the cardiovascular, nervous, and immune system.
It has been shown that NO causes relaxation of the vascular
smooth muscle cells in the cardiovascular system, functions
as a signaling molecule in the nervous system, and is used
by phagocytic cells of the immune system against pathogens.
Some properties of NO, including its ability to kill circulating
tumor cells and its ability to control disease progression, may
contribute to these results (12).
The net effects of NO depend on its concentration, its
target cell, and its interactions with metal ions, proteins,
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and reactive oxygen species (ROS). In tumor cells, tumorassociated NO production may provide a selective growth
advantage with an angiogenic stimulus and promote
cancer progression by inducing DNA damage through
the generation of free radicals on DNA. In addition, NO
production stimulates hyperplasia in normal tissues (13).
To our knowledge, this is the first study showing the
analysis of the T-786C, G894T and intron 4 VNTR (4a/b)
polymorphisms of the eNOS gene identified by using
paraffin-embedded tissues obtained from PCa patients. In
a previous study by Sanli et al. (8), intron 4 VNTR (4a/b)
polymorphism in Turkish patients with PCa was examined
using DNA extracted from blood samples. There are also
few studies on eNOS gene polymorphisms for PCa patients
in different populations (4,12–15).
In the present study, we examined if three well-known
polymorphisms of the eNOS gene were associated with the
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risk of PCa in a Turkish cohort. According to the result
of our study, there was a significant association between 2
eNOS gene polymorphisms (T-786C and G894T) and PCa
(Table, Figures 1 and 2).
To our knowledge, there is only one other study
examining eNOS gene polymorphisms (T-786C, G894T
and intron 4 VNTR) in PCa patients (4). We performed
a similar procedure on paraffin-embedded tissues in
Turkish patients with PCa. We found that the TC genotype
for the T-786C polymorphism was significant. Safarinejad
et al. (4) found that the CC genotype for the T-786C
polymorphism was associated with an increased risk of
PCa and an increased rate of high grade and advanced
disease. Some studies have shown that individuals with
the C allele for the eNOS T-786C polymorphism have
significantly decreased promoter activity compared with
the T allele (16,17). According to Majumdar et al. (18),
the T-786C polymorphism is able to reduce the promoter
activity of the eNOS gene, which is responsible for the
endothelial NO production. Safarinejad et al. (4) also
showed that plasma NO levels were reduced in individuals
with the -786C allele, and they indicated that this result
was associated with high grade and advanced disease (4).
The T-786C polymorphism is located in the promoter
region of the eNOS gene. The region where the RNA
polymerase enzyme binds is important for transcription
of the gene. Polymorphism in this region may result
in increased or decreased NO synthesis. Although
underlying mechanisms in PCa triggered by increased
or decreased levels of NO are not known, this condition
plays an important role in physiological functions and the
disease states.
In the present study, we also examined whether
the GT and TT genotypes for the eNOS G894T gene
polymorphism were associated with PCa risk. Marangoni
et al. (13) suggested that the GG and GT genotypes for the
eNOS G894T polymorphism were associated with PCa
risk, whereas in other population studies it was indicated
that there is no association between G894T and PCa
(4,15,19).
In a study on bladder cancer patients within the
selected Turkish cohort, Verim et al. (20) found that
the frequencies of the eNOS Glu298Asp heterozygous
genotype and T allele were significantly different when
compared with those of the controls. Although studies
were performed on different cancer types, our results were
concordant with those reported by Verim et al. (20).
NO production regulates blood flow specifically in
coronary arteries. Decreasing the basal NO release was
found to be associated with dispositions to hypertension,
thrombosis, atherosclerosis, and vasospasm (21). G-T
transversion at nucleotide position 894 within exon 7
of the eNOS gene results in a replacement of glutamic
acid by aspartic acid at codon 298. This action causes

conformational changes, leading to decrease in the enzyme
activity and changes in the enzyme structure. As a matter
of fact, in a study by Majumdar et al. (18) it was shown that
polymorphism in this region resulted in decreased eNOS
enzyme activity.
As mentioned earlier, there are only a few studies on
eNOS gene polymorphisms for patients with PCa. With
regard to the Turkish population, VNTR polymorphisms
in the intron 4 of Turkish PCa patients have been previously
studied by Sanli et al. (8). We did not find any significant
correlation between intron 4 VNTR (4a/b) polymorphism
and PCa patients, and our results are concordant with
those reported by Sanli et al. (8) (P > 0.05). However, Sanli
et al. (8) did not find any significant difference between
intron 4 VNTR (4a/b) polymorphism and PCa with highgrade or low-grade tumors; they indicated that the VNTR
allele was overrepresented among patients with advanced
stage tumors and bone metastases, but this difference
was not significant for histologic tumor grades between
groups (8). Among populations, there may be differences
between the phenotypic expression and distribution of
eNOS polymorphisms with prevalence and etiology of
PCa studies that included PCa patients from Iran (4) and
Portugal (14) showing that the “a” allele for the intron
4 VNTR (4a/b) polymorphism was a significant and
important risk factor for PCa (P < 0.05).
There are ethnic differences in the distribution of eNOS
variants. Frequencies of eNOS gene polymorphisms have
been shown to vary among different ethnic groups such
as Caucasian, African Americans, Asians, and Mexican
Americans (10). Some genetic variants are more common
in certain populations. Population specificity may reflect
differences in allele frequency distribution. Results
obtained both from our study and other studies revealed
that the bb genotype appeared to be more frequent in the
Turkish population (8,22–24).
With regard to the results from a study by Tsukada et al.
(25) on plasma NO levels and NOS gene polymorphisms,
their findings of the allele frequencies for intron 4 VNTR
(89.8% for the b allele and 10.2% for the a allele) were
parallel to our results (89% for the b allele and 11% for
the a allele). Studies performed by Tsukada et al. (25) and
Song et al. (26) showed that the plasma level of NOx was
significantly lower in the group with an allele. Based on this
observation, it can be suggested that the intron 4 VNTR
polymorphism of the eNOS gene may affect enzyme levels
of eNOS. According to these results, both bb genotype and
elevated NO production may be effective to suppress the
tumor growth, and thus it may have a protective role on
prostatic carcinogenesis (25, 26).
In conclusion, we observed a significant difference
between PCa patients and controls for both T-786C
and G894T polymorphisms of the eNOS gene; on the
other hand, the intron 4 VNTR (a/b) polymorphism of
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eNOS did show any association with PCa. Both the TC
genotype of the T786C polymorphism and the GT and
TT genotypes of the G894T polymorphism of eNOS were
previously found to be associated with PCa risk. Further
studies are needed to clarify the roles of these genotypes
on PCa development.
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